EPS for CASI Pharmaceuticals, Inc. (CASI) Expected At $-0.03

March 15, 2018 - By Hazel Jackson

 EPS for CASI Pharmaceuticals, Inc. (CASI) Expected At $ 0.03
Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.53, from 1.67 in 2017Q2. It dived, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported.
Northern Trust reported 31,034 shares or 0% of all its holdings. Everett Harris & Com Ca holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 10,002 shares. Raymond James Service Advisors Incorporated stated it has 55,135 shares or 0% of all its holdings. Wells Fargo And Communication Mn has 68 shares for 0% of their portfolio. New York-based Morgan Stanley has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Manatuck Hill Ptnrs Limited Liability reported 15,090 shares. Guggenheim Limited Liability reported 12,242 shares or 0% of all its holdings. Howland Capital Mngmt Ltd Llc invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Blackrock reported 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wellington Shields Limited accumulated 489,984 shares or 0.29% of the stock. Moors And Cabot holds 0.01% or 26,053 shares in its portfolio. California Pub Employees Retirement reported 136,518 shares or 0% of all its holdings. Deutsche Bancorp Ag holds 0% or 21 shares in its portfolio. Next Grp Inc stated it has 2 shares or 0% of all its holdings. Commercial Bank Of America De stated it has 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI).

Analysts expect CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report $-0.03 EPS on March, 30.They anticipate $0.02 EPS change or 40.00 % from last quarter’s $-0.05 EPS. After having $-0.03 EPS previously, CASI Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.93% or $0.03 during the last trading session, reaching $3.25. About 50,664 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since March 15, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Ratings Coverage

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 5 analyst reports since October 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, September 22 by Maxim Group. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, January 16. H.C. Wainwright initiated the shares of CASI in report on Thursday, October 29 with “Buy” rating. The stock of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has “Buy” rating given on Monday, August 14 by Maxim Group.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $227.19 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The company's late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

More recent CASI Pharmaceuticals, Inc. (NASDAQ:CASI) news were published by: Marketwatch.com which released: “CASI Pharmaceuticals Inc.” on May 15, 2017. Also Prnewswire.com published the news titled: “CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference” on February 09, 2018. Prnewswire.com‘s news article titled: “CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By …” with publication date: October 13, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: